Another Drug Targeting NOTCH Shows Promise for Desmoid Tumors

The long wait for targeted systemic therapies to manage desmoid tumors could be over after a second drug directed against the Notch pathway has shown promise.

Related Keywords

Germany ,Paris ,France General ,France ,United Kingdom ,London ,City Of ,Sebastian Bauer ,Robinl Jones ,Alliance Clinical Trials In Oncology ,Institute Of Cancer Research ,European Society For Medical Oncology ,Translational Sarcoma Research Group ,University Duisburg ,Cancer Research ,European Society ,Medical Oncology ,Translational Sarcoma Research ,University Duisburg Essen ,Clinical Trials ,Sarcoma ,Desmoid Tumor ,Drug Development ,Malignant Soft Tissue Tumor ,Clinical Research ,Linical Studies ,Magnetic Resonance Imaging Mri ,Magnetic Resonance Imaging ,Ri ,Maging Magnetic Resonance ,Chemotherapy ,Neoplasm ,Tumor ,Alzheimers Disease ,Lzheimer Disease ,Biologic Therapy ,Drug Delivery System ,Europe ,European ,Oncological Medicine ,Spain ,Pain Management ,Rain ,